{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:01:43Z","timestamp":1772136103556,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing a real-world database in Japan. We analyzed 179 patients who underwent 201 elotuzumab treatments. The median time to next treatment (TTNT) with the 95% confidence interval was 6.29\u00a0months (5.18\u20139.20) in this cohort. Univariate analysis showed that patients with any of the following had longer TTNT: no high risk cytogenic abnormalities, more white blood cells, more lymphocytes, non-deviated \u03ba\/\u03bb ratio, lower \u03b2\n                    <jats:sub>2<\/jats:sub>\n                    microglobulin levels (B2MG), fewer prior drug regimens, no prior daratumumab use and better response after elotuzumab treatment. A multivariate analysis showed that TTNT was longer in patients with more lymphocytes (\u2265\u20091400\/\u03bcL), non-deviated \u03ba\/\u03bb ratio (0.1\u201310), lower B2MG (&lt;\u20095.5\u00a0mg\/L) and no prior daratumumab use. We proposed a simple scoring system to predict the durability of the elotuzumab treatment effect by classifying the patients into three categories based on their lymphocyte counts (0 points for\u2009\u2265\u20091400\/\u03bcL and 1 point for\u2009&lt;\u20091400\/\u03bcL) and \u03ba\/\u03bb ratio (0 points for 0.1\u201310 and 1 point for\u2009&lt;\u20090.1 or\u2009\u2265\u200910) or B2MG (0 points for\u2009&lt;\u20095.5\u00a0mg\/L and 1 point for\u2009\u2265\u20095.5\u00a0mg\/L). The patients with a score of 0 showed significantly longer TTNT (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and better survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) compared to those with a score of 1 or 2. Prospective cohort studies of elotuzumab treatment may be needed to validate the usefulness of our new scoring system.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-32426-6","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T13:03:25Z","timestamp":1680095005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa\/lambda ratio or B2 microglobulin"],"prefix":"10.1038","volume":"13","author":[{"given":"Yutaka","family":"Shimazu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Fuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoji","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Onda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Hanamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhito","family":"Takakuwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shosaku","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"32426_CR1","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"32426_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"key":"32426_CR3","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal, M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet 394, 2096\u20132107 (2019).","journal-title":"Lancet"},{"key":"32426_CR4","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1111\/cas.15163","volume":"112","author":"Y Shimazu","year":"2021","unstructured":"Shimazu, Y. et al. Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. Cancer Sci. 112, 5034\u20135045 (2021).","journal-title":"Cancer Sci."},{"key":"32426_CR5","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2018-99-117209","volume":"132","author":"F Jamil","year":"2018","unstructured":"Jamil, F. et al. Efficacy and toxicity profile of elotuzumab for multiple myeloma: A systematic review and meta-analysis. Blood 132, 5640\u20135640 (2018).","journal-title":"Blood"},{"key":"32426_CR6","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 379, 1811\u20131822 (2018).","journal-title":"N. Engl. J. Med."},{"key":"32426_CR7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai, Y. T. et al. Anti-CSl humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112, 1329\u20131337 (2008).","journal-title":"Blood"},{"key":"32426_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","volume":"34","author":"J Kikuchi","year":"2020","unstructured":"Kikuchi, J. et al. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia 34, 180\u2013195 (2020).","journal-title":"Leukemia"},{"key":"32426_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie, B. G. M. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"32426_CR10","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood 127, 2955\u20132962 (2016).","journal-title":"Blood"},{"key":"32426_CR11","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"key":"32426_CR12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/hed.23535","volume":"36","author":"JL Campian","year":"2014","unstructured":"Campian, J. L., Sarai, G., Ye, X., Marur, S. & Grossman, S. A. Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck 36, 1747\u20131753 (2014).","journal-title":"Head Neck"},{"key":"32426_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever, D. et al. A prognostic score for advanced Hodgkin\u2019s disease. N. Engl. J. Med. 339, 1506\u20131514 (1998).","journal-title":"N. Engl. J. Med."},{"key":"32426_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/1097-0142(19830701)52:1<126::AID-CNCR2820520123>3.0.CO;2-Y","volume":"52","author":"HE Ownby","year":"1983","unstructured":"Ownby, H. E., Roi, L. D., Isenberg, R. R. & Brennan, M. J. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 52, 126\u2013130 (1983).","journal-title":"Cancer"},{"key":"32426_CR15","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","volume":"69","author":"I Ray-Coquard","year":"2009","unstructured":"Ray-Coquard, I. et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 69, 5383\u20135391 (2009).","journal-title":"Cancer Res."},{"key":"32426_CR16","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1200\/JCO.2016.67.8045","volume":"34","author":"RP A\u2019Hern","year":"2016","unstructured":"A\u2019Hern, R. P. Restricted mean survival time: An obligatory end point for time-to-event analysis in cancer trials?. J. Clin. Oncol. 34, 3474\u20133476 (2016).","journal-title":"J. Clin. Oncol."},{"key":"32426_CR17","doi-asserted-by":"publisher","first-page":"204062071881669","DOI":"10.1177\/2040620718816699","volume":"10","author":"RM Rifkin","year":"2019","unstructured":"Rifkin, R. M. et al. A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting. Ther. Adv. Hematol. 10, 204062071881669 (2019).","journal-title":"Ther. Adv. Hematol."},{"key":"32426_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMc1206740","volume":"367","author":"D Larson","year":"2012","unstructured":"Larson, D., Kyle, R. A. & Rajkumar, S. V. Prevalence and monitoring of oligosecretory myeloma. N. Engl. J. Med. 367, 580\u2013581 (2012).","journal-title":"N. Engl. J. Med."},{"key":"32426_CR19","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1200\/EDBK_159009","volume":"35","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar, S. V. Updated diagnostic criteria and staging system for multiple myeloma. Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet. 35, e418\u2013e423 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"32426_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/biostatistics\/kxt059","volume":"15","author":"M Wolbers","year":"2014","unstructured":"Wolbers, M., Blanche, P., Koller, M. T., Witteman, J. C. M. & Gerds, T. A. Concordance for prognostic models with competing risks. Biostatistics 15, 526\u2013539 (2014).","journal-title":"Biostatistics"},{"key":"32426_CR21","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/sim.8570","volume":"39","author":"PC Austin","year":"2020","unstructured":"Austin, P. C., Harrell, F. E. & van Klaveren, D. Graphical calibration curves and the integrated calibration index (ICI) for survival models. Stat. Med. 39, 2714\u20132742 (2020).","journal-title":"Stat. Med."},{"key":"32426_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/sim.4780040107","volume":"4","author":"C-H Chen","year":"1985","unstructured":"Chen, C.-H. & George, S. L. The bootstrap and identification of prognostic factors via Cox\u2019s proportional hazards regression model. Stat. Med. 4, 39\u201346 (1985).","journal-title":"Stat. Med."},{"key":"32426_CR23","doi-asserted-by":"crossref","unstructured":"Efron, B. Bootstrap Methods: Another Look at the Jackknife Source: The Annals of\nStatistics, 7(1), 1\u201326. Published by: Institute of Mathematical Statistics http:\/\/www.jstor.org\/stable\/2958830 (1979).","DOI":"10.1214\/aos\/1176344552"},{"key":"32426_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"32426_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40425-018-0395-x","volume":"6","author":"WJ Ho","year":"2018","unstructured":"Ho, W. J. et al. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. J. Immunother. Cancer 6, 84 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"32426_CR26","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","volume":"40","author":"R Sklavenitis-Pistofidis","year":"2022","unstructured":"Sklavenitis-Pistofidis, R. et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell 40, 1358-1373.e8 (2022).","journal-title":"Cancer Cell"},{"key":"32426_CR27","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00277-015-2462-4","volume":"94","author":"A Romano","year":"2015","unstructured":"Romano, A. et al. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann. Hematol. 94, 1875\u20131883 (2015).","journal-title":"Ann. Hematol."},{"key":"32426_CR28","doi-asserted-by":"publisher","first-page":"34784","DOI":"10.18632\/oncotarget.26196","volume":"9","author":"M Ishibashi","year":"2018","unstructured":"Ishibashi, M. et al. Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget 9, 34784\u201334793 (2018).","journal-title":"Oncotarget"},{"key":"32426_CR29","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1038\/s41375-020-0860-7","volume":"34","author":"A Suzuki","year":"2020","unstructured":"Suzuki, A. et al. Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia 34, 3088\u20133090 (2020).","journal-title":"Leukemia"},{"issue":"9","key":"32426_CR30","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41375-021-01172-x","volume":"35","author":"MHS Awwad","year":"2021","unstructured":"Awwad, M. H. S. et al. Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia 35(9), 2602\u20132615 (2021).","journal-title":"Leukemia"},{"key":"32426_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4049\/jimmunol.2000300","volume":"206","author":"P O\u2019Connell","year":"2021","unstructured":"O\u2019Connell, P. et al. SLAMF7 signaling reprograms T cells toward exhaustion in the tumor microenvironment. J. Immunol. 206, 193\u2013205 (2021).","journal-title":"J. Immunol."},{"key":"32426_CR32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","volume":"1","author":"NA Bezman","year":"2017","unstructured":"Bezman, N. A. et al. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Adv. 1, 753\u2013765 (2017).","journal-title":"Blood Adv."},{"key":"32426_CR33","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","volume":"9","author":"KS Campbell","year":"2018","unstructured":"Campbell, K. S., Cohen, A. D. & Pazina, T. Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma. Front. Immunol. 9, 2551 (2018).","journal-title":"Front. Immunol."},{"key":"32426_CR34","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1182\/blood.2020006200","volume":"136","author":"MN Kararoudi","year":"2020","unstructured":"Kararoudi, M. N. et al. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood 136, 2416\u20132427 (2020).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32426-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T13:06:29Z","timestamp":1680095189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32426-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32426"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32426-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2373261\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J. Kanda received honorarium from Bristol-Myers Squibb Co., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Sanofi K.K. and Ono Pharmaceutical Co., Ltd., and is an advisory role in Janssen Pharmaceutical K.K, and Novartis Pharma K.K. T.I. honorarium from Bristol-Myers Squibb Co., Takeda Pharmaceutical Co., Ltd. and Sanofi K.K.; and research funding from Bristol-Myers Squibb Co. K.I. received honorarium from Bristol-Myers Squibb Co., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Celgene K.K., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd. and Meiji Seika Pharma Co. Ltd. S.F. received honorarium from Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Sanofi K.K., Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Co. H.T. received personal fees from Bristol-Myers Squibb Co. (Celgene K.K.), personal fees from Novartis Pharma K.K., grants from Kyowa Kirin Co., Ltd. H.S. reports honoraria from Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Celgene K.K., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Sanofi K.K., AstraZeneca K.K., AbbVie G.K., SymBio Pharmaceuticals Ltd., Eisai Co., Ltd., and Kyowa Kirin Co., Ltd.; and research funding from Pharma Essentia Japan K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Celgene K.K., Novartis Pharma K.K., Sanofi K.K., AstraZeneca K.K., AbbVie G.K., Eisai Co., Ltd., HUYA Bioscience International, LLC., and Chugai Pharmaceutical Co., Ltd.; and scholarship endowment from Astellas Pharma Inc., Teijin Pharma Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd., Sanofi K.K., Taiho Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd. I.M. received personal fees from Bristol-Myers Squibb Co. (Celgene K.K.), personal fees from Novartis Pharma K.K., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., personal fees from Pfizer Japan Inc., during the conduct of the study; grants from Ono Pharmaceutical Co., Ltd., personal fees from Janssen Pharmaceutical K.K, grants from Nippon Shinyaku Co., Ltd., grants from Kyowa Kirin Co., Ltd., grants from Sumitomo Dainippon Pharma Co., Ltd., grants from Shionogi & Co., Ltd., grants from Teijin Pharma limited., grants from Boehringer Ingelheim Co., Ltd., grants from Sanofi K.K., grants from Chugai Pharmaceutical Co., Ltd., grants from Eisai Co., Ltd., grants from MSD K.K, grants from Asahi Kasei Pharma Corporation, grants and personal fees from Astellas Pharma Inc., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants from Japan Blood Products Organization, grants from Nihon Pharmaceutical Co., Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., grants and personal fees from AbbVie GK, grants from Taiho Pharmaceutical Co., Ltd., grants from Mitsubishi Tanabe Pharma Corporation, grants from Nippon Kayaku Co., Ltd., grants from CSL Behring LLC, grants from Mundipharma K.K, grants from Ayumi Pharmaceutical Corporation, grants from Eli Lilly Japan K.K., grants from Actelion Pharmaceuticals Japan Ltd., personal fees from Amgen BioPharma K.K., outside the submitted work. C.S. received honoraria from Janssen Pharmaceutical K.K., Sanofi K.K., and Bristol-Myers Squibb. Co. A. Takaori-Kondo serves as an advisor for Megakaryon and receives research fundings from Ono Pharmaceutical Co., Ltd., DSK, and Cognano. J. Kuroda. received research funding from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Eisai, Bristol-Myers Squibb Co., Sysmex, Dainippon Sumitomo Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., AbbVie GK, Teijin Pharma Ltd. and Otsuka Pharmaceutical Co., Ltd., has received honoraria from Janssen Pharmaceutical K.K, Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Eisai Co., Ltd., SymBio Pharmaceuticals Ltd., Bristol-Myers Squibb Co, Astellas Pharma Inc., Pfizer Japan Inc., Nippon Shinyaku Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., AbbVie GK and Otsuka Pharmaceutical Co., Ltd., and is a consultant for Janssen Pharmaceutical K.K, and Bristol-Myers Squibb Co. The other authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5159"}}